Skip to main
GRDN

GRDN Stock Forecast & Price Target

GRDN Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Guardian Pharmacy Services Inc. demonstrates a strong positive outlook due to its effective integration of advanced technology solutions, which are expected to enhance value-based care conversations and improve operational efficiencies in its recently acquired facilities. The company boasts a significant market share and a robust tech stack that differentiates it within the differentiated pharmacy services sector, contributing to an attractive earnings power opportunity. Additionally, the utilization of robotic dispensing machines has increased efficiency and accuracy, reducing the time to fulfill requests to less than one day, further positioning the company favorably in the competitive landscape.

Bears say

Guardian Pharmacy Services Inc faces multiple risk factors that contribute to a negative outlook on its stock. Key concerns include potential regulatory and reimbursement changes, particularly related to the Inflation Reduction Act (IRA), which may affect the company's profitability and revenue streams. Additionally, challenges such as supply chain disruptions, difficulties in hiring and retaining clinical staff, dependency on technology assets, and the ability to successfully source and integrate acquisitions create further uncertainties that could impede the company's growth and operational effectiveness.

GRDN has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Guardian Pharmacy Services Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Guardian Pharmacy Services Inc (GRDN) Forecast

Analysts have given GRDN a Buy based on their latest research and market trends.

According to 2 analysts, GRDN has a Buy consensus rating as of Jan 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Guardian Pharmacy Services Inc (GRDN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.